T

he immune system constantly scans the body for tumor cells, destroying most of them before they can become a detectable cancer, but sometimes it needs a boost. That’s the thinking behind the new generation of cancer treatments called immunotherapies. One of the most promising versions are CAR-Ts (chimeric antigen receptor T cells).

Two CAR-Ts have been approved by the Food and Drug Administration: Yescarta, developed Kite Pharma (which was bought by Gilead), is used to treat adult patients with certain types of large B-cell lymphoma, and Kymriah, from Novartis, is for a form of acute lymphoblastic leukemia.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I am a big fan of Sharon Begley. I try to read everything by her that I come across. But – subscribe to Stat Plus would just add more emails that I don’t have time to read. I read Megan five days a week, and I often read articles she recommends, but I also read a great many other things and Medicine is not my primary interest. Please don’t do this again. I know you want in increase Stat Plus’ members but please understand that everyone’s time is limited.
    Thank you,
    Norma Frank

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.